Offc Action Outgoing

LASERSCOPE PVP

Laserscope

TRADEMARK APPLICATION NO. 78241828 - LASERSCOPE PVP - N/A

UNITED STATES DEPARTMENT OF COMMERCE

To:	Laserscope (mpetronelli@laserscope.com)
Subject:	TRADEMARK APPLICATION NO. 78241828 - LASERSCOPE PVP - N/A
Sent:	11/13/03 5:30:50 PM
Sent As:	ECom111
Attachments:	Attachment - 1 Attachment - 2 Attachment - 3 Attachment - 4 Attachment - 5 Attachment - 6 Attachment - 7

UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO: 78/241828

APPLICANT: Laserscope

CORRESPONDENT ADDRESS:

Laserscope

3070 Orchard Drive

San Jose, CA 95134-2011

RETURN ADDRESS:

Commissioner for Trademarks

2900 Crystal Drive

Arlington, VA 22202-3514

ecom111@uspto.gov

MARK: LASERSCOPE PVP

CORRESPONDENT’S REFERENCE/DOCKET NO: N/A

CORRESPONDENT EMAIL ADDRESS:

mpetronelli@laserscope.com

Please provide in all correspondence:

1. Filing date, serial number, mark and

applicant's name.

2. Date of this Office Action.

3. Examining Attorney's name and

Law Office number.

4. Your telephone number and e-mail address.

OFFICE ACTION

TO AVOID ABANDONMENT, WE MUST RECEIVE A PROPER RESPONSE TO THIS OFFICE ACTION WITHIN 6 MONTHS OF OUR MAILING OR E-MAILING DATE.

Serial Number 78/241828

The assigned examining attorney has reviewed the referenced application and determined the following. The examining attorney has searched the Office records and has found no similar registered or pending mark which would bar registration under Trademark Act Section 2(d), 15 U.S.C. Section 1052(d). TMEP section 1105.01. However, the examining attorney has determined the following.

REGISTRATION REFUSED -- Mark Fails as a Trademark

The examining attorney refuses registration because the proposed mark does not function as a service mark. Trademark Act Sections 1, 2, 3 and 45, 15 U.S.C. Sections 1051, 1052, 1053 and 1127. It neither identifies and distinguishes the services of the applicant from those of others nor indicates their source. In re Moody's Investors Service Inc., 13 USPQ2d 2043 (TTAB 1989); In re Signal Companies, Inc., 228 USPQ 956 (TTAB 1986); In re Hughes Aircraft Co., 222 USPQ 263 (TTAB 1984); TMEP sections 1301.02(a).

Registration of a designation for a process, method, system, or the like, is sometimes sought on the assumption that a process, or the like, is a service and the name applied to it is registrable as a service mark. However, processes, methods and systems are only ways of doing something. They are not, in and of themselves, activities for the benefit of others. TMEP section 1301.01. In this case, the services are listed as providing a procedure for the treatment of medical conditions. As such, the applicant’s recitation indicates that the mark merely identifies a method. A term, which merely designates a process or method as here, is not registrable as a service mark. In re Universal Oil Products Co., 167 USPQ 245 (TTAB 1970), aff'd, 177 USPQ 456 (C.C.P.A. 1973) (PENEX and PACOL used only in the context of a process and not in association with provision of the services, even though applicant is in the business of rendering services generally and the services are advertised in the same specimen brochure in which the name of the process is used).

The applicant should also note the following additional ground for refusal.

REGISTRATION REFUSED – MARK IS MERELY DESCRIPTIVE

The examining attorney refuses registration on the Principal Register because the proposed mark merely describes the services. Trademark Act Section 2(e)(1), 15 U.S.C. Section 1052(e)(1); TMEP section 1209 et seq. A mark is merely descriptive under Trademark Act Section 2(e)(1), 15 U.S.C. 1052(e)(1), if it describes an ingredient, quality, characteristic, function, feature, purpose or use of the relevant services. In re Gyulay, 820 F.2d 1216, 3 USPQ2d 1009 (Fed. Cir. 1987); In re Bed & Breakfast Registry, 791 F.2d 157, 229 USPQ 818 (Fed. Cir. 1986); In re MetPath Inc., 223 USPQ 88 (TTAB 1984); In re Bright‑Crest, Ltd., 204 USPQ 591 (TTAB 1979); TMEP section 1209.01(b).

The applicant’s mark is LASERSCOPE PVP for a procedure for the treatment of medical conditions. Here, the term PLASERSCOPE merely describes in instrument in use in providing the services and the term PVP merely describes the purpose. Please see the attached evidence establishing the descriptive use of the wording. Therefore, the mark merely describes a feature and characteristic of the services.

Although the examining attorney has refused registration, the applicant may respond to the refusal to register by submitting evidence and arguments in support of registration. If the applicant chooses to respond to the refusal to register, the applicant must also respond to the following informalities.

INFORMALITIES

Incorrect Classification

The applicant has classified the services incorrectly. The applicant must amend the application to classify the goods in International Class 44. 37 C.F.R. Sections 2.33(a)(1)(vi) and 2.85; TMEP sections 805 and 1401.

Recitation of Services

The wording in the recitation of services is unacceptable as indefinite because it does not identify a service and lack sufficient specificity. The applicant must amend the recitation to specify the common commercial name of the services. If there is no common commercial name for the services, the applicant must describe the services and indicate their nature. TMEP section 1301.05. The applicant should also note that in the identification, the applicant should use the common commercial designation for the services, be as complete and specific as possible and avoid the use of indefinite words and phrases. The applicant may not include broad wording such as "services in connection with..." or "such as" or "including" or "and like services" or "systems" or "products" or "concepts" or "not limited to...." TMEP sections 804.08(c) and 1301.05.

The applicant may adopt the following recitation of services, if accurate:

Class 44

Medical health care services in the form of surgery.

Please note that, while an application may be amended to clarify or limit the identification, additions to the identification are not permitted. 37 C.F.R. Section 2.71(b); TMEP section 804.09. Therefore, the applicant may not amend to include any services that are not within the scope of the services recited in the present identification.

Ownership of Prior Registration

If the applicant is the owner of Registration No. 1340456, the applicant must submit a claim of ownership. 37 C.F.R. Section 2.36; TMEP section 812. Please see the attached registration.

CONCLUSION

If the applicant has any questions or needs assistance in responding to this Office action, please telephone the assigned examining attorney.

/IngridCEulin/

Ingrid C. Eulin

Law Office 111

(703) 308-9111 ext 424

(703) 308-7191 fax

(703) 746-8111 alternate fax

How to respond to this Office Action:

To respond formally using the Office’s Trademark Electronic Application System (TEAS), visit http://www.gov.uspto.report/teas/index.html and follow the instructions.

To respond formally via E-mail, visit http://www.gov.uspto.report/web/trademarks/tmelecresp.htm and follow the instructions.

To respond formally via regular mail, your response should be sent to the mailing Return Address listed above and include the serial number, law office and examining attorney’s name on the upper right corner of each page of your response.

To check the status of your application at any time, visit the Office’s Trademark Applications and Registrations Retrieval (TARR) system at http://tarr.gov.uspto.report/

For general and other useful information about trademarks, you are encouraged to visit the Office’s web site at http://www.gov.uspto.report/main/trademarks.htm

FOR INQUIRIES OR QUESTIONS ABOUT THIS OFFICE ACTION, PLEASE CONTACT THE ASSIGNED EXAMINING ATTORNEY.

MAIL-IT REQUESTED: NOVEMBER 13, 2003 10083K

CLIENT:

LIBRARY: NEWS

FILE: US

YOUR SEARCH REQUEST AT THE TIME THIS MAIL-IT WAS REQUESTED:

"LASER SCOPE" AND PVP OR POLY!

NUMBER OF STORIES FOUND WITH YOUR REQUEST THROUGH:

LEVEL 1... 2

LEVEL 1 PRINTED

THE SELECTED STORY NUMBERS:

DISPLAY FORMAT: KWIC

MULTIPLE DOCUMENTS ON A PAGE

Medical Industry Today

January 24, 2002, Thursday

SECTION: DEVICES

LENGTH: 487 words

HEADLINE: Laser to Treat BPH Proves Quick, Effective in Trial

BODY:

... clinical trials.

The Niagara PV Surgical Laser System, which is available in the United States, conducts photo-selective-vaporization (PVP) of the prostate. The device uses a combination of a specific wavelength of high energy 532 nanometer laser light delivered ...

... endoscopic visualization. The high intensity light pulses vaporize and remove obstructive prostate tissue while causing complete hemostasis. The PVP procedure is minimally invasive and done in an outpatient setting.

... site clinical study was initiated to further prove that the operative speed, unmatched clinical results, durability, safety and patient satisfaction of the PVP procedure which were demonstrated by Dr. Reza Malek at the Mayo Clinic over the past three years could be replicated in the ...

... symptom scores decreased by 83 percent and post-void residual volumes decreased by 97 percent, according to Laser scope. Transient and mild dysuria (painful urination) was noted in 5 percent of patients. There were no reported complications or other side ...

... no risk of side-effects and were fast and easy for the physician to perform. These preliminary clinical results further indicate that the Niagara PVP procedure accomplishes all three."

Laserscope designs, manufactures, sells and services a line of medical laser systems and related ...

****************************061118******************************

SEND TO: EULIN, INGRID

TRADEMARK LAW LIBRARY

2101 CRYSTAL PLAZA ARC

MAILBOX 314

ARLINGTON, VIRGINIA 22202-4600
MAIL-IT REQUESTED: NOVEMBER 13, 2003 10083K

CLIENT:

LIBRARY: NEWS

FILE: US

YOUR SEARCH REQUEST AT THE TIME THIS MAIL-IT WAS REQUESTED:

"PHOTO SELECTIVE" AND LASER!

NUMBER OF STORIES FOUND WITH YOUR REQUEST THROUGH:

LEVEL 1... 23

LEVEL 1 PRINTED

DISPLAY FORMAT: KWIC

MULTIPLE DOCUMENTS ON A PAGE

SEND TO: EULIN, INGRID

TRADEMARK LAW LIBRARY

2101 CRYSTAL PLAZA ARC

MAILBOX 314

ARLINGTON VIRGINIA 22202-4600

**********************************00082**********************************

PR Newswire

November 4, 2003, Tuesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS

LENGTH: 673 words

HEADLINE: Laserscope Application for New Medicare Classification for Photo-Selective Vaporization of the Prostate is Accepted;

New Technology Service APC to Become Effective April 1, 2004

DATELINE: SAN JOSE, Calif., Nov. 4

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced that the Centers for Medicare and Medicaid Services (CMS) has notified Laserscope that its application for assignment of Photo-Selective Vaporization of the Prostate (PVP) to treat Benign Prostatic Hyperplasia (BPH) to a new technology Ambulatory Payment Classification (APC) has been ...

... associated reimbursement rates will be forthcoming prior to the reassignment.

"This is extremely exciting news for us," said Eric Reuter, Laserscope's President and CEO. "Demonstrated to be a revolutionary way to treat BPH, PVP possesses both the clinical efficacy and the safety profile that ...

... ensure that the hospital outpatient and physician reimbursement rates for furnishing PVP reflect the appropriate costs of performing the procedure."

About Laserscope

Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. More information about Laserscope can be found on the Company's web site at www.laserscope.com.

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

... risks are detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's public disclosure filings with the SEC, including the most recent Annual Report on Form 10-K and the most recent ...

... Investor Relations Department.

For further information, please contact Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, of Laserscope, +1-408-943-0636; or Tricia Ross, Analyst Contact, or, Linda Chien, General Inquiries, of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope.

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, of Laserscope, +1-408-943-0636, or Tricia Ross, Analyst Contact, or, Linda Chien, General Inquiries, of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: LASERSCOPE INC (96%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope MEDICARE (93%); MEDICAID (83%);

SUBJECT:

... LSCP-application; PRESS RELEASES (90%); MEDICAL DEVICES (90%); APPOINTMENTS (90%); HEALTH INSURANCE (90%); MEDICARE (90%); LASERS (89%); PROSTATE DISEASE (77%); MEDICAID (72%); OUTPATIENT SURGERY CENTERS (71%);

PR Newswire

October 23, 2003, Thursday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS EDITOR

LENGTH: 2190 words

HEADLINE: Laserscope Reports 36% Jump in Third Quarter 2003 Revenues

KEYWORD: bc-CA-Laserscope-Q3-Erns;

BODY:

Third Quarter Highlights:

* GreenLight PV laser systems sold increase 70% over prior quarter

* Unit sales of GreenLight PV fiber-optics grow to approximately ...

... end 2002

* Revises 2003 guidance and issues 2004 expectations

SAN JOSE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its third quarter ended September 30, 2003 jumped ...

... increased significantly on both a year- over-year and sequential basis, driven primarily by the continued adoption of our Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure, and strong domestic and international sales and marketing efforts," said Eric Reuter, Laserscope's President and CEO. "Every day, we are educating a growing number of urologists, healthcare administrators and patients on the clinically-proven, ...

... individuals and our strong quarterly results are evidence of this progress."

Reuter continued, "During the quarter, we sold 34 GreenLight PV(TM) laser systems and 3,414 fibers, compared with 20 systems and 3,075 fibers in the prior quarter.

... rates that have been published by the CMS for 2004," concluded Reuter.

Guidance

The Company revises the following guidance for 2003:

* Laserscope expects that overall revenues will increase due to

continued sales growth of the PVP products. The Company anticipates

that it will ...

... programs for the PVP products.

* For the year, the Company expects net income of $0.10 to $0.11 per

diluted share. Laserscope is narrowing its previously forecasted

range of $0.10 to $0.15 per diluted share as a result of its

continued, significant investment in the ...

... 55%.

* The Company expects to achieve 2004 net income of $0.30 per diluted

share.

Management Conference Call

Management of Laserscope will hold a conference call on Thursday, October 23, 2003, at 8:00 am PDT / 11:00am ...

... five minutes prior to the start time.

Investors will have the opportunity to listen to the conference call live on the Internet through Laserscope's Web site at www.laserscope.com or CCBN at www.fulldisclosure.com . Investors should go to the Web site a few minutes early, as it ...

... 2236 (303-590-3000 for international callers), passcode 556430. A replay of the webcast will be available at Laserscope's Web site.

Additional information on Laserscope including an archive of corporate press releases is also available on the Company's Web site.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

... Relations Department.

For further information, please contact Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Analyst, Tricia Ross, or General Inquiries, Linda Chien, both of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope.

Laserscope

GreenLight PV(TM) Fiber Sales

(Units)

2003 Q1 Q2 Q3 YTD

U.S. Hospitals & Clinics 466 ...

... 490 1,090 1,950

International Customers 0 70 260 100 430

Total 120 560 1,110 1,660 3,450

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Income

Three months ended Nine months ended

(thousands except ...

... capital leases 18 60

Shareholders' equity 18,223 15,482

Total liabilities and shareholders' equity $34,148 $29,163

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Analyst, Tricia Ross, or General Inquiries, Linda Chien, both of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: Laserscope

SUBJECT: bc-CA-Laserscope-Q3-Erns; Earnings; Earnings Projections or Forecasts; Conference Call Announcements COMPANY EARNINGS (90%); FIBER OPTICS (89%); LASERS (89%); FINANCIAL RESULTS (78%); INTERIM FINANCIAL RESULTS (78%); MARKET SEGMENTATION (77%); MEDICAL DEVICES (70%); PHYSICIANS & ...

PR Newswire

July 24, 2003, Thursday SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS EDITOR

LENGTH: 2429 words

HEADLINE: Laserscope Reports 22% Increase in Second Quarter 2003 Revenues

BODY:

Second Quarter Highlights:

* Sales of GreenLight PV laser systems triple and fiber-optics double

over prior quarter

* Strong and growing backlog of laser systems demonstrate continued

traction

* Cash position increases to $5.6 million from $4.7 million at 2002 year

end

SAN JOSE, Calif., July 24 /PRNewswire-FirstCall/ -- Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its second quarter ended June 30, 2003 increased ...

... 2003.

"The second quarter marks the seventh consecutive quarter of year-over-year revenue growth," said Eric Reuter, Laserscope's President and CEO. "We are especially pleased with the tremendous performance of our urology business where growing acceptance of our Benign Prostatic Hyperplasia (BPH) treatment ...

... driving sales. Urologists, hospital administrators and patients alike are recognizing the unmatched, long-term clinical results and patient benefits of the Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure.

"In late April, we introduced a new brand name for our PVP ...

... technology," continued Reuter. "During the quarter, we shipped 20 GreenLight PV(TM) (formerly known as Niagara PV(TM)) laser systems and 3,075 fibers, up considerably from six systems and 1,400 fibers in the previous quarter.

Furthermore, we ended the second quarter with a backlog of 21 GreenLight PV laser systems. We additionally booked eight laser system orders for a new rental program that addresses the desire by many new urologists who are trained ...

... 4.8 million at March 31, 2003 and from $4.7 million at the end of 2002. For the next several quarters, Laserscope expects to continue to fund growth of its urology business with cash flow generated from its aesthetics business and from sales of the GreenLight PV laser systems and fiber-optic devices.

Six-Month Results

For the six months ended June 30, 2003, the Company ...

... successfully meeting our number one goal of growing adoption of the PVP procedure."

Patent Protects Proprietary Technology

In April, Laserscope received a patent for the technology and applications of the Company's GreenLight PV laser. "The patent covers our GreenLight PV laser and fiber-optic delivery device when applied in the treatment of BPH and is potentially extendible to other soft tissue applications," said ...

... first quarter of 2003, Reuter said, "We made good progress on this issue and successfully shipped 20 GreenLight PV laser systems in the second quarter. Our ongoing challenge is to improve our yield and bring our manufacturing output up to full capacity. We are confident that we ...

... adoption within the existing reimbursement environment," concluded Reuter.

2003 Guidance

The Company updates the following guidance for 2003:

-- Laserscope expects that overall laser sales will increase due to

continued growth in PVP products. The Company anticipates that it

will sell 9,000 to 10,000 PVP fiber-optic devices during the year, an

increase from its previous forecast of 7,500. Additionally,

Laserscope believes that sales of aesthetic products will grow

moderately in all markets. The Company expects that aggregate

revenues for the ...

... for the year, the Company expects net income between $0.10 and

$0.15 per share.

Management Conference Call

Management of Laserscope will hold a conference call on Thursday, July 24, 2003, at 8:00 am PDT / 11:00 ...

... five minutes prior to the start time.

Investors will have the opportunity to listen to the conference call live on the Internet through Laserscope's Web site at www.laserscope.com or CCBN's CompanyBoardroom at www.companyboardroom.com . Investors should go to the Web site a few minutes early, as ...

... 2236 (303-590-3000 for international callers), passcode 546780. A replay of the webcast will be available at Laserscope's Web site.

Additional information on Laserscope including an archive of corporate press releases is also available on the Company's Web site.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

... Relations Department.

For further information, please contact Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Scott Malchow, Analyst Contact, or Linda Chien, General Inquiries, both of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope.

Laserscope

GreenLight PV(TM) Fiber Sales

(Units)

2003 Q1 Q2 YTD

U.S. Hospitals & Clinics 466 589 ...

... 490 1,090 1,950

International Customers 0 70 260 100 430

Total 120 560 1,110 1,660 3,450

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Income

Three months ended Six months ended

June 30, ...

... capital leases 32 60

Shareholders' equity 17,123 15,482

Total liabilities and shareholders' equity $30,712 $29,163

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Scott Malchow, Analyst Contact, or Linda Chien, General Inquiries, both of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: Laserscope

SUBJECT: bc-CA-LSCP-2Q-Results; Earnings; Earnings Projections or Forecasts; Conference Call Announcements; Media advisories and invitations LASERS (91%); COMPANY EARNINGS (90%); FINANCIAL RESULTS (90%); INTERIM FINANCIAL RESULTS (90%); FIBER OPTICS (89%); MEDICAL ...

PR Newswire

May 7, 2003, Wednesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS

LENGTH: 1578 words

HEADLINE: Laserscope PVP Clinical Study Results Presented At 98th Annual American Urological Association Meeting

DATELINE: SAN JOSE, Calif., May 7

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced that the results from several clinical studies of the GreenLight PV(TM) (formerly called Niagara PV(TM)) surgical laser system used for Photo-Selective Vaporization of the Prostate (PVP(TM)) to treat Benign Prostatic Hyperplasia (BPH) were presented at the recent 98th Annual Meeting of the ...

... similar patient demographics.

"We are extremely pleased and excited with the clinical results presented at the AUA meeting," said Eric Reuter, Laserscope's President and CEO. "These studies further indicate that the PVP procedure is rapidly gaining credibility and momentum with a much broader group of ...

... lead it to supplant the other minimally invasive but less efficacious procedures," concluded Reuter.

About the GreenLight PV Laser and PVP Procedure

The GreenLight PV system uses very high average and peak powers of a particular wavelength of laser light (532 nanometer or "green" color) delivered through an innovative and proprietary single-use sterile fiber-optic ...

... selectively and quickly vaporize and remove the obstructive prostate tissue virtually bloodlessly and immediately relieve the symptoms associated with BPH. The term "Photo-Selective-Vaporization of the Prostate" (PVP) is used to describe the unique properties that this specific wavelength of light has when treating BPH. The green light completely ...

... treatment area and still maintain visibility and a clinical effect as the green light "selects" the oxyhemoglobin before it is absorbed.

As the laser light passes through the sterile water irrigant and enters the prostate tissue, it is absorbed in a very short distance ( ...

... it possible for many patients to be treated and released with complete symptom relief and no catheterization.

Although there are several other "lasers" and "energy sources" currently used to treat BPH, they all work in different ways from each other and each has one or ...

... proven to yield dramatic and immediate post-operative clinical results, low side effects and long-term durability.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Analyst Contact, Scott Malchow, or General Inquiries, Linda Chien, both of FRB/Weber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: LASERSCOPE INC (92%); LASERSCOPE SURGICAL SYSTEMS (91%); WEILL CORNELL MEDICAL CENTER (75%); Laserscope AMERICAN UROLOGICAL ASSOCIATION (93%); NEWYORK-PRESBYTERIAN HOSPITAL (64%);

SUBJECT: bc-CA-LSCP-Clinical-PVp; Surveys, polls & research studies; Trade Show PROSTATE DISEASE (91%); LASERS (90%); MEDICAL DEVICES (90%); MEDICAL RESEARCH (90%); RESEARCH (90%); CLINICAL TRIALS (90%); CARDIOVASCULAR DEVICES (90%);

PR Newswire

April 30, 2003, Wednesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS, MEDICAL AND TECHNOLOGY EDITORS

LENGTH: 615 words

HEADLINE: Laserscope Receives Patent for Its GreenLight Laser

DATELINE: SAN JOSE, Calif., April 30

KEYWORD: bc-CA-Laserscope-patent;

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced that it has received a patent for the technology and applications for the Company's GreenLight PV(TM) (formerly called Niagara PV(TM)) laser. U.S. Patent Number 6,554,824, entitled "Methods for Laser Treatment of Soft Tissue," covers the use of visible laser light for the treatment of Benign Prostatic Hyperplasia (BPH).

"We are very pleased to have received this extensive patent protection, which provides a competitive barrier to entry," said Eric Reuter, Laserscope's President and CEO. "The patent covers our GreenLight PV laser and fiber-optic delivery device when applied in the treatment of BPH and is potentially extendible to other soft tissue applications. We believe that our ...

... envelopes virtually all technology necessary to create the high power green light energy required to treat BPH using the Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure."

Reuter added, "The key to the success of our procedure lies in the application of high power 532 nanometer, green laser light to the prostatic tissue, allowing urologists to precisely and quickly vaporize tissue without harming the surrounding area. This single technological ...

... results have shown that the procedure provides immediate and complete symptom relief with an extremely low incidence of side effects.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, +1-408-943-0636, both of Laserscope; or Scott Malchow, Analyst Contact, or Linda Chien, General Inquiries, +1-310-407-6555, both of FRBˆWeber Shandwick for Laserscope

COMPANY: LASERSCOPE INC (93%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope THE SEC (57%);

SUBJECT: bc-CA-Laserscope-patent; PATENTS (93%); LASERS (92%); PROSTATE DISEASE (91%); PRESS RELEASES (90%); MEDICAL DEVICES (90%); SURGERY & TRANSPLANTATION (78%); SURGICAL PROCEDURES ( ...

PR Newswire

April 24, 2003, Thursday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS EDITOR

LENGTH: 2204 words

HEADLINE: Laserscope Reports First Quarter 2003 Results;

Revenues Up 32% Over First Quarter 2002 Strong PVP Product Sales and Growing Backlog of Laser Systems

DATELINE: SAN JOSE, Calif., April 24

KEYWORD: bc-CA-Laserscope-Q1-earn;

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its first quarter ended March 31, 2003, increased ...

... quarter of 2002.

"Demand for our products continues to increase in both the urology and aesthetic markets," said Eric Reuter, Laserscope's President and CEO. "There is a growing number of urologists and hospital administrators that understand Laserscope's approach to treating benign prostatic hyperplasia (BPH). This recognition is fueling the rapid adoption of the Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure and driving sales of our PVP laser systems and disposable fiber-optic devices. During the quarter, we shipped six PVP laser systems and over 1,400 fibers. More impressive is our backlog, which ended the quarter with twenty PVP laser systems. These results support our belief that with its unparalleled clinical outcomes and lower cost of overall patient care, the PVP procedure will ...

... driven by our alliance with McKesson Medical and the increasing demand for the wide range of aesthetic procedures that can be performed using Laserscope equipment."

... expenses did not contribute materially to our expenses during the quarter. Legal proceedings arise out of the Company's ordinary course of business and Laserscope expects legal costs will fluctuate from quarter to quarter based on the level of activity.

The Company's cash position increased to $4.8 million at March 31, 2003 from $4.7 million at the end of 2002. For the next several quarters, Laserscope expects to continue to fund growth of its urology business with cash flow generated from its aesthetics business and from sales of the PVP laser systems and fiber-optic devices.

American Urology Association Meeting Activities

As the Company has previously announced, the early results from the multi- ...

... on April 30, the overall results of the Company's multi-site study will be presented in a podium session.

Laserscope will be exhibiting at the AUA meeting and will also use the forum of the meeting to unveil a new name and marketing campaign for its PVP laser system. "We feel that the name Niagara PV, does not fully represent the essence and capability of our laser system. The new name for the product will add the brand recognition that we believe will ultimately promote stronger consumer ...

... remember and allows us the flexibility to extend this technology into other applications," said Reuter.

Update on Industry and Outlook

In Laserscope's discussion of fourth quarter 2002 results, the Company commented that it was experiencing a shortage of some critical components that would likely impact its ability to ship PVP lasers in the first quarter of 2003. "While we made progress on this issue during the first quarter, we are continuing to work with our existing suppliers and have qualified some new suppliers to overcome the shortages," said Reuter. "We completed and shipped six PVP lasers during the quarter, and as mentioned earlier, we built a backlog of twenty units. We expect a resolution to this issue soon, leading to ...

... Services (CMS). While these reductions are beginning to have a short-term negative impact on the rapid growth in sales of Laserscope's BPH treatment products, the Company's management believes that in the long-term, the superior clinical outcomes will prove it to be the ...

... support of our growing base of PVP users in this endeavor."

2003 Guidance

The Company reiterates the following guidance for 2003:

-- Laserscope expects that overall laser sales will increase due to

continued growth in PVP products. The Company anticipates that it

will sell approximately 7,500 PVP fiber-optic devices during the

year, with second quarter sales of these products higher than the

first quarter's. Additionally, Laserscope believes that sales of

aesthetic products will grow moderately in all markets. The Company

expects that aggregate revenues for the ...

... 0.15 per share, with the majority of earnings growth

generated in the latter part of the year.

Management Conference Call

Management of Laserscope will hold a conference call on Thursday, April 24, 2003, at 8:00 a.m. PDT/11:00 ...

... five minutes prior to the start time.

Investors will have the opportunity to listen to the conference call live on the Internet through Laserscope's Web site at www.laserscope.com or CCBN's CompanyBoardroom at www.companyboardroom.com. Investors should go to the Web site a few minutes early, as ...

... A replay of the webcast will be available at CCBN's CompanyBoardroom through May 24, 2003.

Additional information on Laserscope including an archive of corporate press releases is also available on the Company's Web site.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

Laserscope

Niagara(TM) Fiber Sales

2002

Total Q1 Q1

2002 2002 2003

U.S. Hospitals & Clinics 1,070 ...

... U.S. Mobile Service Providers 1,950 70 775

International Customers 430 0 165

Total 3,450 120 1,406

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Operations

Three Months Ended

March 31,

(thousands except per ...

... capital leases 46 60

Shareholders' equity 15,784 15,482

Total liabilities and shareholders' equity $29,336 $29,163

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO of Laserscope, +1-408-943-0636; or analysts, Scott Malchow, or general inquiries, Linda Chien of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: LASERSCOPE INC (94%); LASERSCOPE SURGICAL SYSTEMS (91%); AMERICAN UROLOGY ASSOCIATION (70%); Laserscope

SUBJECT: bc-CA-Laserscope-Q1-earn; Earnings; Earnings Projections or Forecasts LASERS (93%); FIBER OPTICS (90%); MEDICAL DEVICES (90%); COMPANY EARNINGS (90%); HEALTH CARE INDUSTRY (78%); MEDICAL ...

St. Petersburg Times (Florida)

March 27, 2003 Thursday

SECTION: LARGO TIMES; Pg. 6

LENGTH: 724 words

HEADLINE: Laser prostate procedure offers much simpler, shorter recovery

BYLINE: CANDACE RONDEAUX

DATELINE: TARPON SPRINGS

BODY:

... operating room, days in the hospital and maybe a week or more attached to a catheter or try a new laser treatment recently introduced at Helen Ellis Memorial Hospital, possibly cutting his recovery time in half.

"People ...

On Tuesday, Zeltner, 76, was one of the first in line for the minimally invasive treatment, which uses a laser to vaporize an enlarged prostate. And a little more than an hour after Dr. Paul Arnold performed the procedure, ...

... shorter recovery will entice many more men in the Tampa Bay area to try the new treatment, called photo-selective-vaporization of the prostate.

"It's relatively bloodless," Arnold said. "It's quick and effective, and the main thing is that patients don't go ...

... Clearinghouse. Frequent urination at night, problems with flow or bladder infections are common signs of an enlarged prostate.

Officials with Laserscope, the California-based maker of the technology called Niagra PV, estimate roughly 13-million men are diagnosed with the condition each ...

... sent home with instructions to use a catheter.

But with the new technique, Arnold is able to eliminate the enlarged prostate using Laserscope's $150,000 laser system in roughly a half hour. Guided to the prostate through a fiber optic tube, a special green laser pulses light that vaporizes the prostate with unparalleled precision.

"Fifty percent of patients will be able to go home without a ...

... Arnold said.

Arnold was the first physician in Pennsylvania to use the treatment and has instructed dozens of doctors across the nation on photo-selective-prostate vaporization, or PVP, he said.

He also was one of the first to introduce the technique in Florida after moving here about two months ...

... people know about it because it could be a breakthrough."

During the past year, 145 patients were treated with the new PVP laser system as part of a clinical study at six medical centers, including hospitals in New York, Pennsylvania, ...

GRAPHIC:

... Paul Arnold talks with Walt Zeltner, 76, seasonal resident of New Port Richey, after Zeltner underwent a laser procedure on his enlarged prostate Tuesday at Helen Ellis Memorial.

SUBJECT: PROSTATE DISEASE (93%); CARDIOVASCULAR DEVICES (89%); MEDICAL DEVICES (89%); DISEASES & DISORDERS (89%); LASERS (89%); PHYSICIANS & SURGEONS (78%); SURGERY & TRANSPLANTATION (78%); SURGICAL PROCEDURES (78%); DRUG INTERACTIONS & SIDE EFFECTS (71%); ...

St. Petersburg Times (Florida)

March 26, 2003 Wednesday

SECTION: NORTH PINELLAS TIMES; Pg. 1

LENGTH: 730 words

HEADLINE: Prostate procedure brings swift recovery

BYLINE: CANDACE RONDEAUX

DATELINE: TARPON SPRINGS

BODY:

"People ...

... shorter recovery will entice many more men in the Tampa Bay area to try the new treatment, called photo-selective-vaporization of the prostate.

"It's relatively bloodless," Arnold said. "It's quick and effective, and the main thing is that patients don't go ...

... Clearinghouse. Frequent urination at night, problems with flow or bladder infections are common signs of an enlarged prostate.

Officials with Laserscope, the California-based maker of the technology called Niagra PV, estimate roughly 13-million men are diagnosed with the condition each ...

... sent home with instructions to use a catheter.

"Fifty percent of patients will be able to go home without a ...

... Arnold said.

Arnold was the first physician in Pennsylvania to use the treatment and has instructed dozens of doctors across the nation on photo-selective-prostate vaporization, or PVP, he said. He also was one of the first to introduce the technique in Florida after moving here about two months ...

... people know about it because it could be a breakthrough."

During the past year, 145 patients were treated with the new PVP laser system as part of a clinical study at six medical centers, including hospitals in New York, Pennsylvania, ...

GRAPHIC:

... talks with his patient, Walt Zeltner, 76, seasonal resident of New Port Richey after Zeltner underwent a new laser procedure on his enlarged prostate Tuesday at Helen Ellis

SUBJECT: PROSTATE DISEASE (93%); CARDIOVASCULAR DEVICES (89%); MEDICAL DEVICES (89%); DISEASES & DISORDERS (89%); LASERS (89%); SURGERY & TRANSPLANTATION (78%); SURGICAL PROCEDURES (78%); PHYSICIANS & SURGEONS (72%); DRUG INTERACTIONS & SIDE EFFECTS (70%); ...

PR Newswire

February 13, 2003, Thursday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS

LENGTH: 2351 words

HEADLINE: Laserscope Reports Fourth Quarter 2002 Results;

Revenues Increase 32% From Fourth Quarter 2001

KEYWORD: bc-CA-Laserscope-earning;

BODY:

... Momentum for Niagara PV(TM) Systems and Fiber-Optics

SAN JOSE, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its fourth quarter ended December 31, 2002, increased ...

... expectations and was driven by growth in both our core aesthetics business and emerging urology business," said Eric Reuter, Laserscope President and CEO. "Sales of our products for aesthetic procedures remained strong worldwide with the majority of the growth coming from our U.S. sales ...

... revenues were bolstered again by sales growth of our Niagara PV products. During the quarter, we sold eight Niagara PV laser systems and 1,660 Niagara PV disposable fiber-optic delivery devices. When compared to the third quarter of 2002, unit volume of fiber-optics sold increased 50%. Over time, as the installed base of Niagara PV laser systems increases, we expect a growing stream of recurring revenues from the sales of fiber-optics."

... a result of increased activity on existing litigation. Legal proceedings arise out of the Company's ordinary course of business and Laserscope expects legal costs will fluctuate from quarter to quarter based on the level of activity.

"We will continue to invest heavily in the introduction of our new Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure to the market," stated Reuter. "As the initial stages of the launch are behind us, we have shifted our resource ...

... 4.7 million at year end from $4.1 million at the end of the third quarter. For the next several quarters, Laserscope expects to continue to fund growth of Niagara PV with cash flow generated from its aesthetics business and from sales of the Niagara PV system.

...

... Clinical results have shown that the procedure provides immediate and complete symptom relief with an extremely low incidence of side effects.

Laserscope began selling the Niagara PV system and related disposable fiber-optic delivery devices in the first quarter of 2002. Since that time, the Company has sold 32 laser systems and 3,450 disposable fiber-optics. This sales growth shows continuing penetration of each of the target markets, which are U.S. hospitals and ...

... reductions are beginning to have a short-term negative impact on the rapid growth in sales of Niagara PV products, Laserscope believes that in the long-term, the superior clinical outcomes will prove it to be the standard of care.

"We will continue our efforts to ...

... commitment to delivering a quality product for this procedure has stretched some of our vendors to the point where we were unable to fulfill our Niagara PV laser backlog during January 2003 due to a shortage of some critical components. We are working with these suppliers to overcome these issues and are also in the process of developing alternative supply sources for these components. As a result of the components shortage which has delayed shipments of Niagara PV lasers and the typical seasonal decline in elective procedures during the holiday season, we expect procedure volume and fiber-optics sales ...

... lower than in the fourth quarter but to rebound during the second quarter."

The Company is providing the following guidance for 2003:

-- Laserscope expects that overall laser sales will increase due to continued growth in Niagara PV products. The Company anticipates that it will sell ...

... optics during the year, with first quarter sales of these products at lower levels compared to the fourth quarter of 2002. Additionally, Laserscope believes that sales of aesthetic products will grow moderately in all markets. The Company expects that aggregate revenues for the ...

... 0.15 per share, with the majority of earnings growth generated in the latter part of the year.

Management Conference Call

Management of Laserscope will hold a conference call on Thursday, February 13, 2003, at 8:00 AM PST/11:00 ...

... five minutes prior to the start time.

Investors will have the opportunity to listen to the conference call live on the Internet through Laserscope's web site at www.laserscope.com or through CCBN's CompanyBoardroom at www.companyboardroom.com. Investors should go to the web site a few minutes ...

... A replay of the webcast will be available at CCBN's CompanyBoardroom through March 13, 2003.

Additional information on Laserscope including an archive of corporate press releases is also available on the Company's web site.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

Laserscope

Niagara(TM) Fiber Sales

2002

Q1 Q2 Q3 Q4 YTD

U.S. Hospitals & Clinics 50 190 ...

... 490 1,090 1,950

International Customers 0 70 260 100 430

Total 120 560 1,110 1,660 3,450

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Operations

Three months ended Twelve months ended

Dec. 31, ...

... capital leases 60 60

Shareholders' equity 15,482 13,412

Total liabilities and shareholders' equity $29,163 $25,482

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO of Laserscope, +1-408-943-0636, or Scott Malchow, Analyst Contact, or Linda Chien, General Inquiries, of FRBˆWeber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: LASERSCOPE INC (93%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope

SUBJECT: bc-CA-Laserscope-earning; Earnings; Conference Call Announcements LASERS (90%); MEDICAL DEVICES (90%); COMPANY EARNINGS (90%); BIOTECHNOLOGY (79%); ATTORNEYS FEES (70%);

PR Newswire

October 23, 2002, Wednesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS, MEDICAL AND TECHNOLOGY EDITORS

LENGTH: 2277 words

HEADLINE: Laserscope Reports Third-Quarter Increases in Revenues, Earnings and Niagara PV(TM) BPH Sales;

Revenues Up 32% Over Third-Quarter 2001

DATELINE: SAN JOSE, Calif., Oct. 23

KEYWORD: bc-CA-Laserscope-earns;

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its third quarter ended September 30, 2002 increased ...

... 641,000, or $0.04 per share loss, in the same period of 2001.

"We continue to be pleased with our progress," said Eric Reuter, Laserscope President and CEO. "Our domestic aesthetic sales were strong and offset some seasonal softness in our international aesthetic sales, and we showed significant growth in the Niagara PV(TM) disposable fiber-optic product line."

According to Laserscope, the U.S. aesthetics business benefited from excellent execution by the U.S. sales, marketing, clinical, and service teams and the company's strong ... Selling general and administrative expenses continued to be in line with Laserscope's expectations, and were relatively flat as a percentage of revenues. The company added that increases in these expenses relative to 2001 were consistent with its plan to ...

... cash at the end of the quarter, up from $3.8 million at the end of the second quarter. For the next several quarters, Laserscope expects to continue to fund growth of Niagara PV with cash flow from its aesthetic business and from early sales of the Niagara PV system.

...

... share loss, during the same period of 2001.

Strong Growth in Niagara PV Signals Adoption

Reuter noted that Laserscope began selling the Niagara PV system and related disposable fiber-optic delivery devices in the first quarter this year. "To date, we have sold 24 laser systems -- six in the first quarter, and nine in each of second and third quarters -- and approximately 1,800 fiber-optics -- ...

... U.S. mobile service providers and international customers." Reuter added that international fiber sales are front-end loaded together with the laser sale and will not provide a recurring revenue stream for some months to come, unlike domestic fiber- ...

... commitments are fulfilled.

"The growth in fiber sales to each of these sectors is very encouraging," continued Reuter. "It demonstrates rapid adoption of the Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure in the very large benign prostatic hyperplasia (BPH) market. According to industry sources, ...

... extremely low incidence of any side effects or complications," commented Reuter.

"Our stated goal continues to be to have the PVP procedure, which uses Laserscope's Niagara PV system, become the standard of care for BPH worldwide. Given the revenues ranging from $600 to $1,000 per ...

... short- and long-term clinical test results from the Mayo Clinic and other institutions, reinforce our belief that this goal is achievable. We expect the Laserscope BPH treatment solution to be the basis for our future long-term revenue growth," commented Reuter.

Meeting Reimbursement Challenges

He ...

... PVP procedure hold off on their purchases or adoption until the reimbursement climate becomes more attractive," Reuter stated.

Laserscope is pursuing a number of strategies to address this issue. "First, we are supporting our current physician and hospital users in petitioning CMS to ...

... five minutes prior to the start time. Investors will have the opportunity to listen to the conference call live on the Internet through Laserscope's Website at www.laserscope.com or through CCBN's CompanyBoardroom at www.companyboardroom.com. Investors should go to the Website a few minutes early, as ...

... passcode 6258860. A replay of the Webcast will be available at CCBN's CompanyBoardroom through November 23, 2002.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are ...

Laserscope

Niagara(TM) Fiber Sales

2002

Q1 Q2 Q3 YTD

U.S. Hospitals & Clinics 50 190 360 ...

... Providers 70 300 490 860

International Customers 0 70 260 330

Total 120 560 1,110 1,790

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Operations

Three months ended Nine months ended

September 30, ...

... equity $28,322 $25,482

Make Your Opinion Count - Click Here

http://tbutton.prnewswire.com/prn/11690X28177332

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Scott Malchow (Analyst/Investor) or James Hoyne (General Inquiries), both of FRB/Weber Shandwick, +1-310-407-6555, for Laserscope

COMPANY: LASERSCOPE INC (94%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope

SUBJECT: bc-CA-Laserscope-earns; Earnings; Conference Call Announcements PRESS RELEASES (91%); TRENDS (90%); FIBER OPTICS (90%); MEDICAL DEVICES (90%); COMPANY EARNINGS (90%); LASERS (78%);

PR Newswire

July 23, 2002, Tuesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS

LENGTH: 1923 words

HEADLINE: Laserscope Reports Second Quarter Increases in Revenues, Profit and Niagara PV BPH System Sales, Exceeding Expectations

DATELINE: SAN JOSE, Calif., July 23

KEYWORD: bc-CA-Laserscope-Q2;

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its second quarter ended June 30, 2002 were $10.5 ...

... even per share in the first quarter of 2002.

"We are very pleased with the continued progress towards our goals," said Eric Reuter, Laserscope President and CEO. "The second quarter results include higher sales of our Niagara PV(TM) System, and its related disposable fiber- ...

... treatment because of its unique advantages which include immediate symptom relief from a fast, bloodless, and minimally invasive procedure," commented Reuter.

"Laserscope's stated goal is for our proprietary process, the Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure, which uses Laserscope's Niagara PV System, to become the standard of care for BPH. Early indications of market acceptance, which are following on our excellent clinical test results, reinforce our belief that this goal is achievable. We expect the Laserscope BPH treatment solution to contribute incremental future revenues and to be the basis for future growth," continued Reuter.

"The aesthetics business also continues to be strong. As expected in the quarter, we received clearance from the Japanese Ministry of Health and Welfare (MHW) to market the Laserscope Lyra XP(TM) laser system and accessories into the aesthetic market in Japan, allowing our distributor, Japan Medical Equipment Company (JMEC), to sell to the growing ...

... on hair removal procedures," added Reuter.

"In addition, and also as expected, we recently received clearance from the FDA to market our Lyra laser family of products for the non-invasive treatment of wrinkles," stated Reuter. "The clearance adds the fifth major indication for the ...

... able to market the Lyra for the non-invasive treatment of aged and sun-damaged skin, which is one of the fastest growing aesthetic laser procedures. The Lyra system, with certain proprietary and patented system elements, is clinically shown to reduce wrinkles and improve the tone of the skin ...

... forecasted increase in sales and marketing expenses compared to the year-ago-quarter and the first quarter," said Dennis LaLumandiere, Laserscope VP Finance and CFO. "The increases in sales and marketing expenses represent spending to support the Niagara PV launch, as well as to ...

... BPH, which began shipping for revenue in January 2002. We also expect to see moderate increases in revenues from aesthetic lasers in all geographic markets.

Gross margin from products, as a percentage of net product revenues in 2002, is expected to be ...

... 2001. The increases are expected as we continue to invest in educational support as well as marketing programs for the Niagara PV and other lasers. Selling, general and administrative expenses as a percentage of net revenues are expected to be slightly lower than the level in 2001 which was about ...

... expenditures in 2002 are expected to be at levels similar to the 2001 level of $1.1 million.

Management Conference Call

Management of Laserscope will hold a conference call on Tuesday July 23, 2002 at 8:00 a.m. PDT/11:00 ...

... passcode 6105189. A replay of the Webcast will be available at CCBN's CompanyBoardroom through August 23, 2002.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that ...

... risks are detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's most recent forms 10K and 10Q are available upon request from its Investor Relations Department.

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Operations

Three months ended Six months ended

June 30, ...

... equity $27,820 $25,482

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X72114445

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO of Laserscope, +1-408-943-0636; or media, Pam Roberts, or investors, James Hoyne of FRB/Weber Shandwick, +1-415-986-1591, for Laserscope

COMPANY: LASERSCOPE INC (95%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope; Japan Medical Equipment Company

SUBJECT: bc-CA-Laserscope-Q2; Earnings; Conference Call Announcements; Earnings Projections or Forecasts PRESS RELEASES (92%); PROFITS (90%); PROSTATE DISEASE ( ...

... RESULTS (89%); SURGERY & TRANSPLANTATION (89%); SURGICAL PROCEDURES (89%); PHARMACEUTICALS INDUSTRY (88%); HEALTH CARE INDUSTRY (78%); LASERS (78%); MEDICAL EQUIPMENT & SUPPLIES MFG (73%);

PR Newswire April 24, 2002, Wednesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS AND TECHNOLOGY EDITORS

LENGTH: 1445 words

HEADLINE: Laserscope Reports First Quarter Increases in Revenues and Earnings;

Results Exceed Same Quarter Last Year

DATELINE: SAN JOSE, Calif., April 24

KEYWORD: bc-CA-Laserscope-earns;

BODY:

... pleased to report the improved financial results for the quarter relative to the same period last year," said Eric Reuter, Laserscope President and CEO. "Although slightly lower than the fourth quarter of 2001, they demonstrate continued acceptance of our aesthetic products, particularly in the ...

... additional expenses with cash flows from our core aesthetic business. We are targeting the large market opportunity for the treatment of BPH, and expect the Laserscope BPH treatment solution to contribute incremental future revenues and to be the basis for future growth," added Reuter.

"Our goal," continued Reuter, "Is for our proprietary process, the Photo-Selective Vaporization of the Prostate (PVP(TM)) procedure using Laserscope's Niagara PV System, to become recognized as the standard of care for BPH at some time in the near future. ...

... 1.8 million seek drug or other minimally invasive treatments," commented Reuter. "This is a tremendous market opportunity for Laserscope, since we believe that over time, a large number of patients will seek treatment using the Niagara PV equipment and the ...

... improve the products and their position in the market. For example, we have launched our new 'i-solutions' series Aura, Lyra, and Venus lasers beginning this quarter. The 'i solutions' series of products have some unique technological advances and include 'turn-key' internet and information- ...

... fee-for-service' business as part of their practice. We have recently submitted clinical data to the FDA to request clearance to market our Lyra laser family of products for the non-invasive treatment of wrinkles. If we are granted this clearance, we will be able to market the Lyra for one of the fastest growing aesthetic laser procedures which is the non-invasive treatment of aged and sun-damaged skin. This process has been clinically shown to increase the collagen formation over time and reduce the size and appearance of wrinkles," concluded Reuter.

Guidance for 2002

In 2002, we believe that overall laser sales will increase due to sales of our new laser for treatment of benign prostatic hyperplasia ( or enlarged prostate), which began shipping for revenue in January 2002. We expect to continue to see moderate increases in sales of lower-priced office-based aesthetic lasers in all geographic markets.

We expect product gross margin, as a percentage of net product revenues in 2002, to be ...

... approximately 10%. The increases are expected as we continue to invest in educational support as well as marketing programs for the Niagara and other lasers.

We expect capital expenditures in 2002 to be at levels similar to the 2001 level of $1.1 million.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that ...

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Operations

Three Months Ended

March 31,

(thousands except per ...

... equity $25,288 $25,482

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X45164250

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Pam Roberts (General Info/Media), or James Hoyne (Analyst/Investor), both of FRB/Weber Shandwick, +1-415-986-1591, for Laserscope

COMPANY: LASERSCOPE INC (93%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope

SUBJECT: bc-CA-Laserscope-earns; Earnings; Earnings Projections or Forecasts PRESS RELEASES (92%); MEDICAL DEVICES (91%); COMPANY LOSSES (90%); COMPANY EARNINGS (90%); PROSTATE DISEASE (89%); FINANCIAL RESULTS (78%); SURGERY & TRANSPLANTATION (78%); SURGICAL PROCEDURES (78%); LASERS (78%); PRODUCT MANAGEMENT (78%); EARNINGS PER SHARE (76%);

Charleston Gazette (West Virginia)

February 17, 2002, Sunday

SECTION: Life; Pg. P10F

LENGTH: 430 words

HEADLINE: HEALTH NEWS New laser technique relieves prostate condition

BYLINE: Patricia Anstett Knight Ridder Newspapers

BODY:

... common enlarged prostate condition that forces men at midlife to make frequent bathroom trips can be treated with a laser that relieves symptoms immediately with virtually no side effects, says the urologist who developed the procedure.

Urologists have sought for ...

... undergo annually, can cause side effects that include blood loss and impotence.

The new approach - called Niagara PVP (photo-selective vaporization) - is a laser with the strength of an 80-watt light bulb that vaporizes excess prostate tissue, says Dr. Mahmood Hai, the leading ...

... performed 50 of the procedures since December 2000 at Oakwood Annapolis Hospital in Wayne, Mich., and is designated by Laserscope Inc., the manufacturer, as its chief physician trainer.

The 20-minute procedure is performed with local anesthesia and intravenous sedation and requires no ...

... can be used on prostate glands of varying sizes, including those that are completely obstructed, Hai said.

Doctors thread a laser tip through a thin tube into the urethra. Then the laser applies energy that makes excess tissue evaporate. Patients typically go home within a few hours and return to ...

... in a day or two. Most patients do not need to use temporary catheters to urinate, as surgery patients do. Other lasers, using slightly less energy, don't immediately destroy all tissue and haven't been considered widely effective, said Hai, who has worked for a decade with lasers to treat BPH.

The treatment, federally approved last year, costs $3,000 and usually is covered by insurance, Hai said. ...

... 25 years as a urologist, Hai said at a recent news conference.

For more information, call Laserscope at (800) 356-7600 or visit its Web site, www.laserscope.com.

COMPANY: LASERSCOPE INC (75%);

SUBJECT: technology medicine health research PROSTATE DISEASE (94%); PHYSICIANS & SURGEONS (90%); MEN (90%); LASERS (89%); CARDIOVASCULAR DEVICES (77%); MEDICAL DEVICES (77%); RESEARCH (69%);

PR Newswire

February 15, 2002, Friday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS, TECHNOLOGY AND MEDICAL EDITORS

LENGTH: 1110 words

HEADLINE: Laserscope Reports Fourth Quarter Increases in Revenues and Net Income;

Fourth Quarter 2001 Results Exceed Expectations

DATELINE: SAN JOSE, Calif., Feb. 15

KEYWORD: bc-CA-Laserscope-earning;

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that revenues for its fourth quarter ended December 31, 2001 were $9.6 ...

... income of $186,000 or $0.01 per share.

"We are very pleased to report the improved financial results for the quarter," said Eric Reuter, Laserscope President and CEO. "They are the outcome of increased focus on sales of our core aesthetic product line and better performance in most of our ...

... core business. We are targeting the large market opportunity for the treatment of benign prostatic hyperplasia ("BPH" or enlarged prostate), and expect the Laserscope BPH treatment solution to contribute incremental future revenues and to be the basis for future growth going forward."

"As we have previously reported," continued Reuter, "the results from the on-going clinical studies for the Photo-Selective Vaporization of the Prostate (PVPTM) procedure using Laserscope's Niagara PV system, continue to support our experience and the experience of our clinical investigators that this procedure will become recognized as the standard of care ...

... United States alone, and at least twice that many in the rest of the world. This is a tremendous market opportunity for Laserscope since we believe that over time, a large number of these procedures will be done using the Niagara PV equipment and the related proprietary single-use fiber-optic devices."

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that ...

LASERSCOPE FINANCIAL SUMMARY

(Unaudited)

Condensed Consolidated Statements of Operations

Three months ended Twelve months ended

December 31, ...

... equity $25,482 $24,087

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X07816681

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, +1-408-943-0636, both of Laserscope; or Pam Roberts, or investors, Elizabeth Saghi, both of FRBˆWeber Shandwick, +1-415-986-1591, for Laserscope

COMPANY: LASERSCOPE INC (96%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope

SUBJECT: bc-CA-Laserscope-earning; Earnings PRESS RELEASES (92%); COMPANY LOSSES (91%); FINANCIAL RESULTS (90%); COMPANY EARNINGS (90%); EARNINGS ...

... MEDICAL DEVICES (90%); COMPUTING & TECHNOLOGY (90%); PROSTATE DISEASE (89%); INTERIM FINANCIAL RESULTS (78%); INVESTIGATIONS (78%); LASERS (78%); MEDICAL RESEARCH (78%); PHARMACEUTICALS INDUSTRY (72%); MARKET SEGMENTATION (70%);

PR Newswire

February 6, 2002, Wednesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS, TECHNOLOGY AND MEDICAL EDITORS

LENGTH: 984 words

HEADLINE: Laserscope Announces St. Vincent Charity Hospital is the First in Ohio To Perform a New, Minimally Invasive Prostate Procedure;

Advanced Laser Technology Provides Urologists and Patients With Breakthrough Results

DATELINE: SAN JOSE, Calif., Feb. 6

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced that St. Vincent Charity Hospital is the first site in the state of Ohio to perform a new, minimally invasive laser treatment for enlarged prostate, which affects over 13 million men who are newly diagnosed with BPH each year ...

... pursued training in this procedure so that I could bring this option to my patients here in Cleveland. Niagara PV(TM) Laser Treatment is definitely a breakthrough. Now patients can have a simple, 20-minute laser procedure, which is minimally invasive, highly effective and with very few risks."

Eric Reuter, President and CEO of Laserscope added, "The results experienced at St. Vincent Charity Hospital are consistent with intermediate results from our multi-site clinical evaluation of the Niagara PV Surgical Laser System (see Laserscope press release dated January 23, 2002, titled Laserscope Announces Intermediate Results from Multi-Site Clinical Evaluation of Niagara PV For BPH). The multi-site clinical study was initiated to further prove that the operative speed, unmatched clinical results, durability, safety, and patient satisfaction of the Laserscope Photo-Selective-Vaporization of the Prostate (PVPTM) procedure which were demonstrated by Dr. Reza Malek at the Mayo Clinic in Rochester, MN, ...

... causes significant bleeding and can require patients to leave the hospital with a catheter in place.

This new procedure is conducted with the Laserscope Niagara PV and can be administered on an outpatient basis under local or light anesthesia, does not cause blood loss, is relatively painless, and has an extremely quick recovery period with excellent results.

How Laserscope Niagara Laser Treatment Helps Patients

Laserscope Niagara PV Laser Treatment works by completely vaporizing the excess prostate tissue quickly, immediately sealing the thin (1-2mm deep) ...

... thin zone allows for quick and painless recovery. The procedure is both extremely fast (average of 20 minutes) and effective.

"The laser is delivered through a fiber optic probe, that is the thickness of a hair, into the cavity via an endoscope inserted through the ...

... St. Vincent Charity Hospital Is the First in Ohio to Perform a New, Minimally Invasive Prostate Procedure .)

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that ...

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X24699182

SOURCE Laserscope

COMPANY: LASERSCOPE INC (93%); LASERSCOPE SURGICAL SYSTEMS (91%); NIAGARA PV SURGICAL (73%); Laserscope; St. Vincent Charity Hospital ST VINCENT CHARITY HOSPITAL (93%);

SUBJECT: bc-CA-LSCP-Ohio-Prostate; New Products and Services LASERS (93%); PRESS RELEASES (92%); APPOINTMENTS (90%); MEDICAL DEVICES (90%); PROSTATE DISEASE (89%); MEN (89%); RESEARCH ( ...

Knight Ridder/Tribune News Service

Detroit Free Press

February 2, 2002, Saturday

SECTION: LIFESTYLE

KR-ACC-NO: K0284

LENGTH: 455 words

HEADLINE: Technique relieves prostate condition

BYLINE: By Patricia Anstett

BODY:

Urologists have sought for ...

... annually, can cause side effects that include blood loss and impotency.

The new approach _ called Niagara PVP, for photo-selective vaporization _ is a laser with the strength of an 80-watt light bulb that vaporizes excess prostate tissue, says Dr. Mahmood Hai, the leading ...

... performed 50 of the procedures since December 2000 at Oakwood Annapolis Hospital in Wayne, Mich., and is designated by Laserscope Inc., the manufacturer, as its chief physician trainer.

The 20-minute procedure is performed with local anesthesia and intravenous sedation and requires no ...

... can be used on prostate glands of varying sizes, including those that are completely obstructed, Hai said.

Doctors thread a laser tip through a thin tube into the urethera. Then the laser applies energy that makes excess tissue evaporate. Patients typically go home within a few hours and return to ...

The treatment, federally approved last year, costs $3,000 and usually is covered by insurance, Hai said. ...

... 25 years as a urologist, Hai said Monday at a news conference.

For more information, call Laserscope at 800-356-7600 or visit its Web site at

http://www.laserscope.com/

___

Visit the Freep, the World Wide Web site of the Detroit Free Press, ...

COMPANY: LASERSCOPE INC (71%);

Detroit Free Press

January 29, 2002 Tuesday METRO FINAL EDITION

SECTION: BODY & MIND; Pg. 3H

LENGTH: 545 words

HEADLINE: TECHNIQUE RELIEVES PROSTATE CONDITION

BYLINE: PATRICIA ANSTETT FREE PRESS MEDICAL WRITER

BODY:

...

... annually, can cause side effects that include blood loss and impotency.

The new approach -- called Niagara PVP, for photo-selective vaporization -- is a laser with the strength of an 80-watt light bulb that vaporizes excess prostate tissue, says Dr. Mahmood Hai, the leading ...

... Hai has performed 50 of the procedures since December 2000 at Oakwood Annapolis Hospital in Wayne and is designated by Laserscope Inc., the manufacturer, as its chief physician trainer.

The 20-minute procedure is performed with local anesthesia and intravenous sedation and requires no ...

... can be used on prostate glands of varying sizes, including those that are completely obstructed, Hai said.

Doctors thread a laser tip through a thin tube into the urethera. Then the laser applies energy that makes excess tissue evaporate. Patients typically go home within a few hours and return to ...

The treatment, federally approved last year, costs $3,000 and usually is covered by insurance, Hai said. ...

... 25 years as a urologist, Hai said Monday at a news conference.

For more information, call Laserscope at 800-356-7600, visit its Web site at www.laserscope.com. or call Oakwood Health Line at 800-543-9355 anytime.

Many men forgo cancer tests

...

COMPANY: LASERSCOPE INC (69%); MICHIGAN INTEGRATED DELIVERY NETWORK INC (58%);

Business Wire

January 28, 2002, Monday

SECTION: HEALTHWIRE

DISTRIBUTION: Business Editors and Health/Medical Writers

LENGTH: 794 words

HEADLINE: Oakwood Annapolis Hospital is First in the World to Offer Revolutionary Laser Prostate Surgery

DATELINE: WAYNE, Mich., Jan. 28, 2002

Niagara(TM) Bloodless Photo-Selective Vaporization of the Prostate Procedure Cuts Recovery Time to Days, Not Weeks; Oakwood Annapolis Physician Mahmood Hai, M.D, ...

... Procedure

Oakwood Annapolis Hospital has announced it is the first hospital worldwide to begin using the revolutionary Niagara PVP(TM) laser photo-selective vaporization procedure (PVP) for benign prostatic hyperplasia (BPH). The 20-minute procedure, performed under local anesthetic, ...

Oakwood Annapolis Hospital's breakthrough Niagara PVP system and KTP/532nm laser were developed by Laserscope(c)(San Jose, Calif.) in consultation with Dr. Hai.

Oakwood Annapolis Hospital is the first and, currently, the only hospital in the world to perform the Niagara PVP procedure and own a KTP laser machine. Dr. Hai has performed over 50 procedures with the new laser since December 2000, and confirms its effectiveness in his training sessions. "Niagara PVP allows a much less invasive, and therefore, ...

... replace existing BPH procedures in the next several years," Dr. Hai explained.

Because of its unprecedented high power, the KTP laser pulses, delivered through a fiber the thickness of a hair inserted in the urinary passage, completely vaporize obstructive prostate tissue. The laser seals the surrounding area creating a virtually bloodless procedure. The procedure generally takes around 20 minutes and is generally ...

... not required to wear a catheter, and can return to their normal lives within two days.

Dr. Hai has been performing laser surgery for BPH since 1991. In 1997, Hai, realizing the increasing need for a more powerful laser, approached Laserscope to develop the next generation laser. Over the next few years, Hai and Laserscope worked together to create the 80-watt KTP/nm laser machine. Dr. Hai oversaw and conducted all clinical studies. Dr. Hai recently completed two years of clinical ...

SUBJECT:

... 91%); SURGERY & TRANSPLANTATION (90%); SURGICAL PROCEDURES (90%); MEN (85%); CARDIOVASCULAR DEVICES (75%); MEDICAL DEVICES (75%); LASERS (75%); ANTIINFECTIVES (70%);

Business Wire

January 28, 2002, Monday

DISTRIBUTION: Business Editors

LENGTH: 940 words

HEADLINE: Newstream.com Digest: Revolutionary Laser Prostate Surgery, Nintendo Cuts Price of Game Boy Advance, 'The Lion King' to Tour America, and other free multimedia content for journalists

DATELINE: Jan. 28, 2002

Oakwood Annapolis Hospital is First in the World to Offer Revolutionary Laser Prostate Surgery

Oakwood Annapolis Hospital has announced it is the first hospital worldwide to begin using the revolutionary Niagara PVP(tm) laser photo-selective vaporization procedure (PVP) for benign prostatic hyperplasia (BPH). The 20-minute procedure, performed under local anesthetic, ...

Medical Industry Today

January 24, 2002, Thursday

SECTION: DEVICES

LENGTH: 487 words

HEADLINE: Laser to Treat BPH Proves Quick, Effective in Trial

BODY:

LASERSCOPE (San Jose, CA) announced Wednesday that Niagara PV Surgical Laser System relieved the symptoms of benign prostatic hyperplasia in all of the patients treated in 20 minutes in clinical trials.

... Malek at the Mayo Clinic over the past three years could be replicated in the hands of other physicians," Eric Reuter, Laserscope president and CEO, said in a statement. "We are very excited but not surprised that these preliminary clinical results from the multi-site ...

... easy for the physician to perform. These preliminary clinical results further indicate that the Niagara PVP procedure accomplishes all three."

Laserscope designs, manufactures, sells and services a line of medical laser systems and related energy delivery devices for the office, outpatient surgical center and hospital markets. The company's stock is listed ...

SUBJECT: LASERS (92%); CLINICAL TRIALS (90%); PROSTATE DISEASE (90%); RESEARCH (89%); MEDICAL DEVICES (89%); MEDICAL RESEARCH (89%); ...

PR Newswire

January 23, 2002, Wednesday

SECTION: FINANCIAL NEWS

DISTRIBUTION: TO BUSINESS, TECHNOLOGY AND MEDICAL EDITORS

LENGTH: 1387 words

HEADLINE: Laserscope Announces Intermediate Results From Multi-Site Clinical Evaluation of Niagara PV(TM) for BPH;

Results Unequaled By Any Other Therapy

DATELINE: SAN JOSE, Calif., Jan. 23

KEYWORD: bc-CA-Laserscope-Results;

BODY:

Laserscope (Nasdaq: LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced intermediate results from its multi-site clinical evaluation of the Niagara PV(TM) Surgical Laser System used for the Photo-Selective-Vaporization of the Prostate (PVP(TM)) in the treatment of Benign Prostatic Hyperplasia (BPH), known as enlarged prostate.

The intermediate results from the ...

... Niagara PVP(TM) Product and Procedure

"We developed the Niagara to meet a tremendous market need," said Eric Reuter, Laserscope President and CEO. "Over 13 million men in the United States alone are diagnosed with BPH each year and over ...

... skepticism as well. This skepticism was based on the fact that numerous other approaches which have been tried for this procedure, including several other laser technologies, have caused disappointment because of the clinical compromises that were necessarily made. We believe that the results of this trial will help dispel this skepticism, create ...

... TM) system uses a unique and proprietary combination of a specific wavelength of high energy 532 nanometer (green) laser light delivered in a chain of pulses called StarPulse(TM) through a single-use sterile fiber ...

... sale in the US and will be available in certain select countries worldwide beginning in the Spring of 2002. Contact Laserscope for more details regarding workshop and training dates and locations.

About Laserscope

Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that ...

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X24454311

SOURCE Laserscope

CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, +1-408-943-0636, both of Laserscope; or media, Pam Roberts, or investors, Elizabeth Saghi, both of FRB/Weber Shandwick, +1-415-986-1591, both for Laserscope

COMPANY: LASERSCOPE INC (92%); LASERSCOPE SURGICAL SYSTEMS (91%); Laserscope BPH MARKET (90%);

SUBJECT: bc-CA-Laserscope-Results; PRESS RELEASES (92%); MEDICAL DEVICES (91%); PROSTATE DISEASE (90%); LASERS (90%); CARDIOVASCULAR DEVICES (89%); BIOTECHNOLOGY (79%); COMPUTING & TECHNOLOGY (79%); MEDICAL RESEARCH (78%); DISEASES & DISORDERS (78%); ...

Business Wire

May 10, 2001, Thursday

SECTION: HEALTHWIRE

DISTRIBUTION: Business Editors/Health & Medical Writers

LENGTH: 498 words

HEADLINE: Laserscope Announces FDA Approval of New Surgical System for the Treatment of BPH

DATELINE: SAN JOSE, Calif., May 10, 2001

KEYWORD: CA-LASERSCOPE;

Laserscope (Nasdaq:LSCP) today announced that it has received approval from the U.S. Food and Drug Administration to market its new high power KTP laser system specifically for the treatment of Benign Prostatic Hyperplasia (BPH).

In commenting on the news, Eric Reuter, Laserscope President and CEO said, "We are very excited about the approval and encouraged that the FDA has cleared our new system specifically for this indication in such ...

Reuter added, "As I have mentioned in previous communications, we believe that this procedure, known as photo-selective vaporization of the prostate, or PVP, will be ultimately recognized as the best treatment available for this disease. Our three-year follow-up ...

CONTACT: Laserscope

Eric Reuter, 408/943-0636 (President & CEO)

Dennis LaLumandiere, 408/943-0636 (CFO)

COMPANY: LASERSCOPE INC (92%); LASERSCOPE SURGICAL SYSTEMS (91%); AMERICAN UROLOGY ASSOCIATION (73%); FOOD & DRUG ADMINISTRATION (94%);

SUBJECT:

... FDA APPROVALS (91%); MEDICAL RESEARCH (90%); PROSTATE DISEASE (90%); MEDICAL DEVICES (86%); BIOTECHNOLOGY INDUSTRY (78%); LASERS (77%); CLINICAL TRIALS (73%); DRUG INTERACTIONS & SIDE EFFECTS (73%); GENETIC SCIENCE & BIOTECHNOLOGY (63%);

Computerworld

November 9, 1992

SECTION: IN DEPTH; From Art to Part; Pg. 81

LENGTH: 767 words

HEADLINE: Desktop manufacturing flavors;

Finding the right method is not always easy. Here are six techniques, including pros and cons of each

BYLINE: By Anil (Neil) Chaudhry

BODY:

... a part layer by layer in a vat of photocurable liquid that hardens when hit by an ultraviolet laser.

Advantages:

Many resins available with varying properties.

New, patented laser scanning and part-building techniques minimize part shrinkage and distortion.

Parts can have both internal and external contours and shapes.

...

... ultraviolet lamp to expose an entire layer at a time, as opposed to tracing the profile of a layer with a laser beam as done in 3D's systems.

Advantages:

Virtually no limits on part shape, including intricate part- ...

... Other equipment average: under 10 sq ft.)

Laminated object manufacturing

Helisys, Inc., Torrance, Calif.

A laser cuts an adhesive-coated sheet of paper that is laminated layer by layer to make a 3-D part. ...

... can absorb moisture and cause distortion and delamination.

Moisture absorption affects stability, part accuracy and shelf life.

Selective laser sintering

DTM Corp., Austin, Texas

A carbon dioxide laser scans a layer of fine powder. Because the powder is kept close to its melting point, it melts, fuses and solidifies wherever the laser scans. In building successive layers, the laser must penetrate to the appropriate depth to fuse the top layer and the one below.

Advantages:

Builds wax models in a ...

GRAPHIC: CW Photo, Selective laser sintering

SUBJECT: LASERS (89%); ADHESIVES & SEALANTS (77%);

****************************061120******************************

SEND TO: EULIN, INGRID

TRADEMARK LAW LIBRARY

2101 CRYSTAL PLAZA ARC

MAILBOX 314

ARLINGTON, VIRGINIA 22202-4600
MAIL-IT REQUESTED: NOVEMBER 13, 2003 10083K

CLIENT:

LIBRARY: NEWS

FILE: US

YOUR SEARCH REQUEST AT THE TIME THIS MAIL-IT WAS REQUESTED:

"PHOTO SELECTIVE" AND LASER!

NUMBER OF STORIES FOUND WITH YOUR REQUEST THROUGH:

LEVEL 1... 23

LEVEL 1 PRINTED

DISPLAY FORMAT: KWIC

MULTIPLE DOCUMENTS ON A PAGE

SEND TO: EULIN, INGRID

TRADEMARK LAW LIBRARY

2101 CRYSTAL PLAZA ARC

MAILBOX 314

ARLINGTON VIRGINIA 22202-4600

**********************************00087**********************************